| Table 2: The included trials scored according to the risk of bias criteria. |
| | | A | B | C | D | E | F | G | H | I | J | K | L |
| |
Tang and Sun 1996 [22] | − | − | − | − | − | ? | + | ? | + | + | − | + | |
Yu et al. 2004 [23] | − | − | − | − | − | + | + | ? | + | + | + | + | |
Wei et al. 2005 [24] | − | − | − | − | − | − | − | ? | + | + | + | − | |
Xu et al. 2007 [25] | − | − | − | − | − | + | + | ? | + | + | + | + | |
Chen and Jing 2008 [26] | + | − | − | − | − | − | + | ? | + | + | + | + | |
Yu et al. 2010 [27] | + | − | − | − | − | + | + | ? | + | + | + | + | |
Zhang et al. 2011 [28] | − | − | − | − | − | + | + | ? | + | + | + | + | |
Zhu and Huang 2011 [29] | − | − | − | − | − | + | + | ? | + | + | + | + |
|
|
A: adequate sequence generation; B: concealment of allocation; C: Blinding (patient); D: blinding (investigator); E: blinding (assessor); F: intention-to-treat analysis (ITT analysis); G: incomplete outcome data addressed(drop-outs); H: free of selective reporting; I: similarity at baseline; J: cointerventions constant; K: compliance acceptable; L: timing outcome assessments similar. +: Yes, −: No, ?: Unclear.
|